43.40
-0.10 (-0.23%)
| Previous Close | 43.50 |
| Open | 43.60 |
| Volume | 377,700 |
| Avg. Volume (3M) | 1,627,255 |
| Market Cap | 23,587,682,304 |
| Price / Earnings (TTM) | 26.46 |
| Price / Earnings (Forward) | 20.45 |
| Price / Sales | 4.46 |
| Price / Book | 8.48 |
| 52 Weeks Range | |
| Earnings Date | 24 Mar 2025 |
| Profit Margin | 14.33% |
| Operating Margin (TTM) | 14.05% |
| Diluted EPS (TTM) | 1.65 |
| Quarterly Revenue Growth (YOY) | 1.50% |
| Quarterly Earnings Growth (YOY) | 57.10% |
| Total Debt/Equity (MRQ) | 121.06% |
| Current Ratio (MRQ) | 0.500 |
| Operating Cash Flow (TTM) | 1.24 B |
| Levered Free Cash Flow (TTM) | 176.66 M |
| Return on Assets (TTM) | 5.28% |
| Return on Equity (TTM) | 31.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | HENLIUS | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | -0.50 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| HENLIUS | 24 B | - | 26.46 | 8.48 |
| BEIGENE | 221 B | - | - | 8.31 |
| INNOCARE | 30 B | - | - | 3.19 |
| EVEREST MED | 19 B | - | - | 3.78 |
| ASCENTAGE-B | 17 B | - | - | 86.39 |
| INNOVENT BIO | 126 B | - | - | 8.83 |
|
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 51.34% |
| % Held by Institutions | 14.71% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |